Загрузка...
CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing
ROS1 rearrangement is a validated therapeutic driver gene in non‐small cell lung cancer (NSCLC) and represents a small subset (1–2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi‐targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib...
Сохранить в:
| Опубликовано в: : | Thorac Cancer |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons Australia, Ltd
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5928353/ https://ncbi.nlm.nih.gov/pubmed/29517860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12617 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|